510(k) device
AHMED ClearPath Glaucoma Drainage Device
New World Medical, Inc. · Implant, Eye Valve (KYF, Class II) · First FDA decision Jan 18, 2019, newest Jan 18, 2019Glaucoma
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
2
Naming "AHMED ClearPath Glaucoma"
MAUDE reports
0
Brand "AHMED ClearPath Glaucoma", since 2015
PubMed studies
1
Mentioning "AHMED ClearPath Glaucoma"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing AHMED ClearPath Glaucoma Drainage Device
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 0 of 1 decisions filed under this name.
FDA's records could not be loaded.
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "AHMED ClearPath Glaucoma", any status and sponsor, newest update first.
State University of New York at BuffaloAcademic, hospital or other
NCT04542616 · 80 participants · Start Aug 13, 2020 · Primary completion Jul 31, 2024
Device: Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantation · For: Glaucoma
Sites: Buffalo, New York
Duke UniversityAcademic, hospital or other
NCT04468633 · 76 participants · Start Dec 17, 2020 · Primary completion Jun 29, 2023
Device: Baerveldt 350 implant; Ahmed ClearPath 350 implant · For: Glaucoma
Sites: Durham, North Carolina
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "AHMED ClearPath Glaucoma", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code KYF
3,772 reports: 1,109 malfunction, 2,659 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "AHMED ClearPath Glaucoma"[tiab]. The summary above synthesizes these.
- A novel retrobulbar/intraconal surgical approach with combined cataract extraction and a modified AHMED ClearPath 250mm2 tube in the ciliary sulcus with an inferior sclerotomy in black and Afro-Latino patients with advanced glaucoma: a 6-month retrospective study.
Laroche D, Calderon I, Nwokeji I · Front Ophthalmol (Lausanne) · 2026
Other devices of this type
Also filed under product code KYF.
- Ahmed® Glaucoma Valve Model FP8New World Medical, Inc. · 510(k) 2023
- iStent infinite Trabecular Micro-Bypass System, Model iS3Glaukos Corporation · 510(k) 2022
- XEN Glaucoma Treatment SystemAllergan, Inc. · 510(k) 2016
- Molteno3 Glaucoma ImplantInnovative Ophthalmic Products, Inc. (Iop) · 510(k) 2015
- MOLTENO3Iop, Inc. · 510(k) 2006
- Express Mini Glaucoma ShuntOptonol, Ltd. · 510(k) 2003
- Ex-Press Minature Glaucoma Implant, Models R-20, R-30, R-50, Sts VersionsOptonol, Ltd. · 510(k) 2002
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.